摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 3-{4-[(3-bromobenzyl)oxy]phenyl}propanoate | 691904-05-9

中文名称
——
中文别名
——
英文名称
methyl 3-{4-[(3-bromobenzyl)oxy]phenyl}propanoate
英文别名
methyl 4-[(3-bromophenyl)methoxy]benzenepropanoate;methyl 3-[4-[(3-bromophenyl)methoxy]phenyl]propanoate
methyl 3-{4-[(3-bromobenzyl)oxy]phenyl}propanoate化学式
CAS
691904-05-9
化学式
C17H17BrO3
mdl
——
分子量
349.224
InChiKey
RDDLNQRAFTVRBN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    437.9±30.0 °C(Predicted)
  • 密度:
    1.345±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.2
  • 重原子数:
    21
  • 可旋转键数:
    7
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.24
  • 拓扑面积:
    35.5
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

  • 作为反应物:
    描述:
    methyl 3-{4-[(3-bromobenzyl)oxy]phenyl}propanoate(1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride四(三苯基膦)钯 、 sodium carbonate 、 三乙胺 作用下, 以 甲醇甲苯 为溶剂, 生成 methyl 4-[[3-(2-thiazolyl)phenyl]methoxy]benzenepropanoate
    参考文献:
    名称:
    Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists
    摘要:
    G protein-coupled receptor 40 (GPR40) is being recently considered to be a new potential drug target for the treatment of type 2 diabetes because of its role in the enhancement of free fatty acid-regulated glucose-stimulated insulin secretion in pancreatic beta-cells. We initially identified benzyloxyphenylproparoic acid (1b) (EC50 = 510 nM), which was designed based on the structure of free fatty acids, as a promising lead compound with GPR40 agonist activity. Chemical modification of compound 1b led to the discovery of 3-{4-[(2',6'-dimethylbiphenyl-3-yl)methoxy]-2-fluorophenyl}propanoic acid (4p) as a potent GPR40 agonist (EC50 = 5,7 nM). Compound 4p exhibited acceptable pharmacokinetic profiles and significant glucose-lowering effects during an oral glucose tolerance test in diabetic rat;. Moreover, no hypoglycemic event was observed even after administration of a high dose of compound 4p to normal fasted rats. These pharmacological results suggest that GPR40 agonists might be novel glucose-dependent insulin secretagogues with little or no risk of hypoglycemia.
    DOI:
    10.1021/jm101405t
  • 作为产物:
    描述:
    3-溴苄溴 在 sodium hydride 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 2.25h, 以72%的产率得到methyl 3-{4-[(3-bromobenzyl)oxy]phenyl}propanoate
    参考文献:
    名称:
    ALKOXYPHENYLPROPANOIC ACID DERIVATIVES
    摘要:
    公开号:
    EP1731505B1
点击查看最新优质反应信息

文献信息

  • [EN] 3-(4-BENZYLOXYPHENYL)PROPANOIC ACID DERIVATIVES<br/>[FR] DERIVES D'ACIDE 3-(4-BENZYLOXYPHENYL) PROPANOIQUE
    申请人:TAKEDA PHARMACEUTICAL
    公开号:WO2005063729A1
    公开(公告)日:2005-07-14
    The present invention provides a novel compound represented by the formula (I) wherein each symbol is as defined in the specification, a salt thereof and a prodrug thereof having a superior GPR40 receptor function modulating action, which can be used as an insulin secretagogue, an agent for the prophylaxis or treatment of diabetes and the like. They unexpectedly show superior GPR40 receptor agonist activity, and also show superior properties as a pharmaceutical product, such as stability and the like. Thus, they can be safe and useful pharmaceutical agents for the prophylaxis or treatment of GPR40 receptor related diseases in mammals.
    本发明提供了一种由公式(I)表示的新的化合物,其中每个符号如说明书中所定义,以及其盐和前药,具有优越的GPR40受体功能调节作用,可用作胰岛素分泌剂,用于预防或治疗糖尿病等的药剂。它们出人意料地显示出优越的GPR40受体激动剂活性,并且还显示出作为药物产品的优越性质,如稳定性等。因此,它们可以成为预防或治疗哺乳动物中与GPR40受体相关疾病的既安全又有用的药物。
  • Alkoxyphenylpropanoic Acid Derivatives
    申请人:Yasuma Tsuneo
    公开号:US20070213364A1
    公开(公告)日:2007-09-13
    The present invention aims at provision of a novel compound having a GPR40 receptor function modulating action, which is useful as an insulin secretagogue, an agent for the prophylaxis or treatment of diabetes and the like. The compound represented by the formula: wherein each symbol is as defined in the description, a salt thereof, and a prodrug thereof of the present invention unexpectedly have a superior GPR40 receptor agonistic activity and superior properties as pharmaceutical products such as stability and the like, and can be safe and useful pharmaceutical agents as agents for the prophylaxis or treatment of GPR40 receptor-related pathology or diseases in mammals.
    本发明旨在提供一种新型化合物,具有GPR40受体功能调节作用,可用作胰岛素分泌剂,用于预防或治疗糖尿病等药物。本发明的化合物由以下式表示:其中每个符号如描述中所定义,其盐和其前药,意外地具有优越的GPR40受体激动活性和优越的药物特性,如稳定性等,并且可以作为安全和有用的药物代理剂,用于哺乳动物的GPR40受体相关病理或疾病的预防或治疗。
  • Receptor Function Regulator
    申请人:Fukatsu Kohji
    公开号:US20090012093A1
    公开(公告)日:2009-01-08
    The GPR40 receptor function regulator of the present invention, which comprises a compound having an aromatic ring and a group capable of releasing cation is useful as an insulin secretagogue or an agent for the prophylaxis or treatment of diabetes and the like.
    本发明的GPR40受体功能调节剂包括具有芳香环和能够释放阳离子的基团的化合物,可用作胰岛素分泌剂或预防或治疗糖尿病等疾病的药剂。
  • 3-(4-Benzyloxyphenyl) propanoic acid derivatives
    申请人:Yasuma Tsuneo
    公开号:US20070149608A1
    公开(公告)日:2007-06-28
    The present invention provides a novel compound represented by the formula (I) wherein each symbol is as defined in the specification, a salt thereof and a prodrug thereof having a superior GPR40 receptor function modulating action, which can be used as an insulin secretagogue, an agent for the prophylaxis or treatment of diabetes and the like. They unexpectedly show superior GPR40 receptor agonist activity, and also show superior properties as a pharmaceutical product, such as stability and the like. Thus, they can be safe and useful pharmaceutical agents for the prophylaxis or treatment of GPR40 receptor related diseases in mammals.
    本发明提供一种新型化合物,其表示为式(I),其中每个符号如规范中所定义,其盐和前药具有优越的GPR40受体功能调节作用,可用作胰岛素分泌促进剂、糖尿病预防或治疗剂等。它们意外地表现出优越的GPR40受体激动剂活性,并且还表现出优越的药物产品特性,如稳定性等。因此,它们可以作为安全和有用的药物剂量,用于哺乳动物的GPR40受体相关疾病的预防或治疗。
  • Receptor Function Regulation Agent
    申请人:Fukatsu Kohji
    公开号:US20080167378A1
    公开(公告)日:2008-07-10
    An agent for regulating 14273 receptor function, which is useful as a preventing or treating drug for diabetes mellitus, hyperlipidemia or the like, is provided. An agent for regulating 14273 receptor function comprising a compound containing an aromatic ring and a group capable of releasing a cation.
    提供了一种用于调节14273受体功能的药物代理,可用作预防或治疗糖尿病、高脂血症等疾病。该调节14273受体功能的药物代理包含一种含有芳香环和能释放阳离子的基团的化合物。
查看更多